Marvin L. Peyton

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
OBJECTIVE To assess the safety of rapidly dissolving buprenorphine/naloxone sublingual tablets (BNX-RDT) in opioid-dependent patients. METHODS This open-label, 24-week extension study enrolled patients who completed primary trials of BNX-RDT. Daily tablet doses ranged from 5.7 to 17.1 mg. The primary endpoint was safety; secondary assessments included(More)
  • 1